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Persistent pulmonary hypertension of the newborn (PPHN) is characterized by elevated pulmonary vascular
resistance resulting in right-to-left shunting of blood and hypoxemia. PPHN is often secondary to parenchymal lung
disease (such as meconium aspiration syndrome, pneumonia or respiratory distress syndrome) or lung hypoplasia
(with congenital diaphragmatic hernia or oligohydramnios) but can also be idiopathic. The diagnosis of PPHN is
based on clinical evidence of labile hypoxemia often associated with differential cyanosis. The diagnosis is confirmed
by the echocardiographic demonstration of – (a) right-to-left or bidirectional shunt at the ductus or foramen ovale
and/or, (b) flattening or leftward deviation of the interventricular septum and/or, (c) tricuspid regurgitation, and finally
(d) absence of structural heart disease. Management strategies include optimal oxygenation, avoiding respiratory
and metabolic acidosis, blood pressure stabilization, sedation and pulmonary vasodilator therapy. Failure of these
measures would lead to consideration of extracorporeal membrane oxygenation (ECMO); however decreased need
for this rescue therapy has been documented with advances in medical management. While trends also note
improved survival, long-term neurodevelopmental disabilities such as deafness and learning disabilities remain
a concern in many infants with severe PPHN.
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Persistent pulmonary hypertension of newborn (PPHN)
is secondary to failure of normal circulatory transition at
birth. It is a syndrome characterized by elevated pulmonary
vascular resistance (PVR) that causes labile hypoxemia due
to decreased pulmonary blood flow and right-to-left shunt-
ing of blood. Prompt diagnosis and management, including
a timely referral to a tertiary care center can dramatically
improve outcome. Its incidence has been reported as 1.9
per 1000 live births (0.4–6.8/1000 live births) with mortality
rate ranging between 4–33% [1]. This syndrome compli-
cates the course of about 10% of term and preterm infants
with respiratory failure and remains a source of consider-
able morbidity and mortality. This review includes a discus-
sion of fetal circulation and circulatory transition at birth,
as well as the pathophysiology, diagnosis, management and
long term complications of PPHN.* Correspondence: vinay.sharma@hcmed.org
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Pulmonary hypertension with reduced pulmonary blood
flow is a normal physiologic state in the fetus. This is
because the placenta, not the lung, serves as the organ
of gas exchange. Most of the right ventricular output
crosses the ductus arteriosus to the aorta (approximately
8-10% of combined ventricular output in an ovine fetus
and 13% -21% in human fetuses) [2-4]. Even though pul-
monary vascular cross-sectional area increases with fetal
lung growth, PVR increases with gestational age when
corrected for lung or body weight, suggesting that pul-
monary vascular tone increases during late gestation.
Multiple pathways appear to be involved in maintaining
high pulmonary vascular tone prior to birth. Apart from
mechanical factors (fluid-filled lung), hypoxic pulmonary
vasoconstriction and circulating vasoconstrictors such as
endothelin-1 and products of the prostaglandin pathway
(i.e. leukotriene and thromboxane) play a significant role
in maintaining high fetal PVR [5].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lective serotonin reuptake inhibitors (SSRIs) during
the last half of pregnancy has been associated with an
increased incidence of PPHN in at least three human
population studies [8-11]. While the mechanism by
which SSRIs induce pulmonary hypertension in newborn
is not known, it is speculated that higher drug-induced
serotonin levels result in pulmonary vasoconstriction.
However, recent studies have questioned the associ-
ation between maternal SSRI intake and PPHN [12,13].
Furthermore, the severity of PPHN has not been well
described and a recent report observed no differences
in right pulmonary artery Doppler pulsatility index (PI)
in fetuses of mothers exposed to SSRI antidepressants
[14]. At present, maternal physical and psychological
well-being should be the primary factor guiding anti-
depressant therapy during pregnancy and postpartum
period.
The fetus is in a physiological state of hypoxemia
(relative to postnatal standards) with PaO2 of around
25 mmHg, a level that promotes normal growth and
differentiation of pulmonary vascular cells and sup-
ports normal branching morphogenesis [15]. However,
a normal fetus is not hypoxic and adequate oxygen de-
livery to the fetal tissues is maintained by multiple
mechanisms including high cardiac output in utero,
high hemoglobin level in the term fetus, and presence
of fetal hemoglobin (HbF) with high oxygen affinity
(Figure 1).
Transitional circulation
A series of circulatory events take place at birth to en-
sure a smooth transition from fetal to extra-uterine
life. Clamping of the umbilical cord removes the low
resistance placental circulation, increasing systemic
arterial pressure. Simultaneously, various mechanisms
operate to rapidly reduce pulmonary arterial pressure
and increase pulmonary blood flow. The most import-
ant stimulus to promote pulmonary vasodilation ap-
pears to be ventilation of the lungs and an increase in
oxygen tension [5]. There is improved oxygenation of
the pulmonary vascular bed, further decreasing PVR
[16]. An eight-fold increase in pulmonary blood flow
occurs, which raises left atrial pressure, closing the for-
amen ovale. As PVR drops lower than systemic vascu-
lar resistance (SVR), there is a reversal of flow across
the ductus arteriosus (from aorta to pulmonary artery
or left-to-right). The increase in arterial oxygen satur-
ation leads to closure of the ductus arteriosus and
ductus venosus. In the final phase of neonatal pulmon-
ary vascular transition, a further decline in PVR is ac-
companied by rapid structural remodeling of the entire
pulmonary bed, from the main pulmonary arteries to
the capillaries [17].Mediators of circulatory transition at birth
Vascular endothelium releases several vasoactive prod-
ucts that play a primary role in pulmonary transition at
birth. Pulmonary endothelial nitric oxide (NO) produc-
tion increases markedly at the time of birth. Oxygen is
believed to be an important catalyst for this increased
NO production, although the precise mechanism is not
clear. It increases oxidative phosphorylation and the
release of red blood cell ATP which is a pulmonary
vasodilator during fetal life and a potential stimulus for
endothelial NO production [18,19]. In intrapulmonary
arteries isolated from near-term fetal sheep, both basal
and stimulated NO release increase with escalating
oxygen tension [20]. The shear stress resulting from
increased pulmonary blood flow and increased oxygen-
ation also induce endothelial nitric oxide synthase
(eNOS) expression, thus contributing to NO-mediated
pulmonary vasodilation after birth [5]. Nitric oxide ex-
erts its action through soluble guanylate cyclase (sGC)
and cGMP (Figure 2). The importance of the NO-
cGMP pathway in facilitating normal transition has
been demonstrated by acute or chronic inhibition of
nitric oxide synthase (NOS) in fetal lambs, which
produces pulmonary hypertension following delivery
[21,22]. Data indicate that eNOS dysfunction induced
through increased levels of asymmetric dimethyl argin-
ine (ADMA), a competitive endogenous inhibitor of
NOS [23], or by decreased synthesis of the NOS
substrate L-arginine [24], may result in pulmonary
vasoconstriction.
The arachidonic acid-prostacyclin pathway also plays
an important role in the transition at birth. The cycloox-
ygenase enzyme acts on arachidonic acid to produce
prostaglandin endoperoxides. Prostaglandins activate ad-
enylate cyclase to increase cAMP concentrations in vas-
cular smooth muscle cells (Figure 2). Cyclooxygenase-1
in particular is upregulated during late gestation, leading
to an increase in prostacyclin production in the third
trimester and early postnatal life [25,26]. Inhibition of
prostacyclin production by non-steroidal anti-inflammatory
drugs (NSAIDs) during late pregnancy has been associated
with PPHN although this association has been recently
called into question [27].
Finally, atrial natriuretic peptide (ANP), B-type natri-
uretic peptide (BNP) and C-type natriuretic peptide
(CNP) dilate fetal pulmonary vasculature by increasing
cGMP through particulate guanylate cyclase (pGC) [28]
and may play a role in pulmonary vascular transition at
birth (Figure 2).
Pathophysiology of PPHN
Disruption of normal neonatal circulatory transition
results in failure to resolve fetal pulmonary hyperten-
sion and leads to the persistence of fetal pulmonary
Figure 1 Fetal and postnatal (adult) circulation: in fetuses, placenta is the organ of gas exchange. The umbilical vein carries oxygenated blood
from the placenta has the highest fetal oxygen saturation of approximately 80%. Oxygen saturation in various blood vessels is shown in crimson
circles. Oxygenated blood is streamed through the ductus venosus and along the left margin of the inferior vena cava. In the heart, oxygenated
blood gets shunted across the foramen ovale (FO) to the left heart to supply the cerebral and coronary circulation. Poorly oxygenated blood
from the upper half of the body goes to the right side of the heart, the main pulmonary artery and gets shunted through the ductus arteriosus
(DA) to the descending aorta. Blood in the descending aorta has a saturation of around 55 %, and this blood flows back to placenta for oxygenation
through umbilical arteries. In spite of relative hypoxia, adequate oxygen delivery to the fetal tissues is maintained by (a) high cardiac output, (b) high
hemoglobin level in the term fetus and (c) the presence of fetal hemoglobin (HbF) with high oxygen affinity. The saturation gradient across the
placenta (85 – 55 = 30%) is similar to the saturation gradient across the lungs in adults (98 – 70% = 28%) but is achieved at a much lower partial
pressure of oxygen (PO2 ~ 32 mmHg in the umbilical vein) in the fetus compared to the adult (PaO2 ~ 95 mmHg) limiting the fetal risk for oxygen
toxicity. (copyright Satyan Lakshminrusimha).
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decreases the blood flow to the lungs. Ventilation-
perfusion (VQ) mismatch (Figure 3) and extrapul-
monary right-to-left shunting of deoxygenated blood
across the patent foramen ovale (PFO) and patent
ductus arteriosus (PDA) result in cyanosis. Differen-
tial cyanosis (saturation in the lower limb is 5-10%
lower than right upper limb) occurs due to pulmon-
ary artery to aorta shunt through the PDA (Figure 3).
If the PDA is closed and the shunt exclusively is at
the PFO level, the degree of cyanosis is similar in
both upper and lower limbs. Labile hypoxemia
(marked change in oxygen saturation with minimal or
no change in ventilator settings) is characteristic ofPPHN and is due to change in the volume of right-
to-left shunt secondary to subtle changes in the deli-
cate balance between PVR and SVR.
Classification
PPHN can be characterized as one of four types:
(1)Maladaptation: Secondary to lung parenchymal
diseases such as meconium aspiration syndrome
(MAS), respiratory distress syndrome (RDS), or
pneumonia
(2)Maldevelopment: Lung with normal parenchyma
and remodeled pulmonary vasculature, also known
as idiopathic PPHN
Figure 2 Endothelium derived vasodilators – prostacyclin (PGI2) and nitric oxide (NO) and vasoconstrictor (endothelin, ET-1). Cyclooxygenase
(COX) and prostacyclin synthase (PGIS) are involved in the production of prostacyclin. Prostacyclin acts on its receptor (IP) in the smooth muscle
cell and stimulates adenylate cyclase (AC) to produce cyclic adenosine monophosphate (cAMP). Cyclic AMP is broken down by phosphodiesterase 3A
(PDE 3A, the enzyme most prevalent in vasculature) in the smooth muscle cell. Milrinone inhibits PDE 3A and increases cAMP levels in
arterial smooth muscle cells and cardiac myocytes resulting in pulmonary (and systemic) vasodilation and inotropy. Nitric oxide (NO)
stimulates PDE 3A [151,152]. Endothelin is a powerful vasoconstrictor and acts on ET-A receptors in the smooth muscle cell and increases
ionic calcium concentration. A second endothelin receptor (ET-B) on the endothelial cell stimulates NO release and vasodilation. Endothelial
nitric oxide synthase (eNOS) produces NO which diffuses from the endothelium to the smooth muscle cell and stimulates soluble guanylate
cyclase (sGC) enzyme to produce cyclic guanosine monophosphate (cGMP). Cyclic GMP is broken down by PDE5 enzyme in the smooth
muscle cell. Sildenafil inhibits PDE5 and increases cGMP levels in pulmonary arterial smooth muscle cells. Natriuretic peptides stimulate
particulate guanylate cyclase (pGC) to produce cGMP. Cyclic AMP and cGMP reduce cytosolic ionic calcium concentrations and induce
smooth muscle cell relaxation and pulmonary vasodilation. Nitric oxide is a free radical and can avidly combine with superoxide anions to
form a toxic vasoconstrictor, peroxynitrite. Hence, the bioavailability of NO in a tissue is determined by the local concentration of superoxide
anions. Hyperoxic ventilation with 100% oxygen can increase the risk of formation of superoxide anions in the pulmonary arterial smooth
muscle cells and limit the bioavailability of NO and stimulate PDE5 activity [81]. Medications used in PPHN are shown in black boxes
(copyright Satyan Lakshminrusimha).
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seen in CDH and other causes of pulmonary
hypoplasia (oligohydramnios secondary to
Potter’s Syndrome, renal disease or chronic
leakage of amniotic fluid)
(4)Intrinsic obstruction: high viscosity due to
polycythemia resulting in intravascular obstruction
and elevated PVRMaladaption/Parenchymal lung diseases resulting in
secondary PPHN
a) Meconium aspiration syndrome (MAS) in newborns
leads to acute respiratory failure with a mortality of up
to 10% [29]. Meconium causes chemical pneumonitis and
surfactant inactivation that leads to ventilation-perfusion
mismatch. Resulting hypoxemia and hypercarbia cause
pulmonary vasoconstriction and PPHN. Structural studies
Figure 3 Pathophysiology of PPHN. Parenchymal lung disease and ventilation-perfusion (V/Q) mismatch result in hypoxemia. Increased pulmonary
vascular resistance results in reduced pulmona ry blood flow and right to left shunt through PDA and/or PFO. Pulmonary hypertension is often
associated with systemic hypotension with deviation of the interventricular septum to the left. The right subclavian artery (and blood flowing
to the right upper extremity) is always preductal. The left subclavian artery may be preductal, juxtaductal or postductal. Hence, preductal
oxygen saturations should be obtained from the right upper extremity and compared with lower extremity to assess differential cyanosis.
PA – pulmonary artery; RV – right ventricle; LV – left ventricle; TR – tricuspid regurgitation; RA – right atrium; LA – left atrium; PDA – patent
ductus arteriosus; PFO – patent foramen ovale. (copyright Satyan Lakshminrusimha).
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aspiration suggest that antecedent pulmonary vascular
abnormalities exacerbated the postnatal pulmonary
hypertension [30]. Decreased eNOS expression has
also been reported in umbilical venous endothelial cell
cultures from human infants with meconium staining
who develop PPHN [31]. Meconium components in-
cite an inflammatory response with release of cytokines
and increase the production of vasoconstrictors in-
cluding endothelin and thromboxane [32]. The inci-
dence of MAS has decreased in developed countries
but continues to be prevalent in resource-limited set-
tings often associated with asphyxia [33].
Management of a neonate born through meconium
stained amniotic fluid has changed dramatically over thelast decade. Amnioinfusion, suctioning at the perineum
and tracheal suctioning in vigorous infants did not alter
the incidence of MAS in multicenter randomized trials
[34-36]. The current guidelines recommend tracheal
suctioning only if the infant born through meconium
stained amniotic fluid is not vigorous at birth [37].
Recent data from a randomized trial and a translational
study have pushed further to question the benefit of
tracheal suctioning of meconium at birth even if the
newborn is not vigorous [38,39]. Additional studies are
required to evaluate the effect of tracheal suctioning in
MAS and the incidence and severity of PPHN.
b) Pneumonia and sepsis often present with elevated
PVR associated with systemic hypotension and de-
creased SVR. In addition, some infants with sepsis have
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hypertension due to elevated left atrial pressures [40].
c) Pulmonary hypertension in premature infants: Al-
though PPHN is traditionally considered a disease of
term and late preterm infants, it is increasingly being
diagnosed in extremely preterm infants [41]. Some pre-
term infants with RDS present with PPHN in the first
few days of life [42] while preterm infants with broncho-
pulmonary dysplasia (BPD) may be diagnosed with
pulmonary hypertension later in the hospital course or
after discharge from the Neonatal Intensive Care Unit
(NICU). Preterm infants with fetal growth restriction
and born after prolonged rupture of membranes are at
higher risk for developing pulmonary hypertension [43].
Pulmonary vascular disease significantly increases mor-
bidity and mortality in BPD [44].
Maldevelopment/Idiopathic PPHN (“Black-lung PPHN)
Some cases of PPHN are not secondary to parenchymal
lung disease and are referred to as idiopathic or “black-
lung” (referring to paucity of pulmonary vascularity and
absence of lung disease) PPHN. Idiopathic pulmonary
hypertension is secondary to remodeled pulmonary ar-
teries, characterized by smooth muscle hyperplasia and
extension of smooth muscle in intra-acinar arteries. The
abnormal structural remodeling of the pulmonary circu-
lation as seen in PPHN affects the responsiveness to
vasodilator stimuli, and may prevent the access of NO
to the vascular smooth muscle cells [45]. Maternal use
of NSAIDs during third trimester of pregnancy can lead
to premature closure of ductus arteriosus [46] and
“black-lung” PPHN. Ovine fetal ligation or constriction
of ductus arteriosus can produce similar vascular changes
and is widely used to replicate PPHN in newborn lambs,
showing the same pulmonary vascular findings as idio-
pathic pulmonary hypertension [47].
Underdevelopment / Pulmonary hypoplasia
Congenital diaphragmatic hernia (CDH) is developmen-
tal defect in the diaphragm separating the thorax and
the abdomen and is the most important cause of pul-
monary hypoplasia resulting in PPHN. This defect leads
to a herniation of the abdominal viscera into the thor-
acic cavity. CDH occurs in 1/2,500 to 5,000 live births.
CDH has a mortality rate of 20-30% and the degree of
associated pulmonary hypoplasia and the severity of pul-
monary hypertension remain the major determinants of
survival [48]. Pulmonary vascular abnormalities in CDH
include a decreased number of pulmonary arteries per
unit lung volume and peripheral muscularization of
small arteries, with medial and adventitial thickening
[49]. In spite of marked improvement in survival of
PPHN resulting from other causes, the mortality and
need for ECMO remain high in infants with CDH.Pulmonary hypoplasia secondary to renal dysfunction
and oligohydramnios or thoracic dystrophy can be asso-
ciated with pulmonary hypertension [50-52]. Prolonged
rupture of membranes is also a risk factor for pulmonary
hypertension in preterm infants [53].
Alveolar capillary dysplasia (ACD)
Alveolar capillary dysplasia is generally associated with
malalignment of the pulmonary veins (ACD/MPV) and
produces respiratory failure early in life and carries a
mortality rate that approaches 100% [54]. Recent reports
of infants presenting with fulminant symptoms of ACD/
MPV well beyond the neonatal period, even as late as
7 months of age, have begun to emerge, challenging the
established phenotype and offering the possibility that
long-term survivors with milder forms of the disease
may exist. [55] FOXF1 transcription factor gene or dele-
tions upstream to FOXF1 were identified in 40% of cases
[56]. Blood testing to screen for these defects is now
available, but a negative result does not preclude the
diagnosis, and histological examination of lung tissue re-
mains the gold standard for diagnosis. A lung biopsy to
rule out ACD should be considered for neonates who do
not respond to conventional medical management or fail
attempts at ECMO decannulation.
Diagnosis
In a term or near-term infant with respiratory distress,
the initial evaluation should include simultaneous meas-
urement of pre- and post-ductal oxygen saturation, a
chest X-ray and an arterial blood gas. Hypoxemia
disproportionate to the severity of parenchymal disease
on a chest radiograph should suggest idiopathic PPHN
(or cyanotic heart disease). Evidence of the underlying
parenchymal disease such as RDS, MAS, or pneumonia
may be seen on chest X-ray in secondary PPHN. A
complete blood count with differential is often obtained
on admission to evaluate for high hematocrit level (poly-
cythemia and increased viscosity contributing to intrin-
sic vascular obstruction) and to evaluate the risk of
underlying infection.
Differentiating PPHN from cyanotic CHD soon after
admission is of paramount importance. Preductal and
postductal oxygen saturation/PaO2 measurements are
used to differentiate PPHN from structural heart disease.
Saturation differences of > 5-10% or PaO2 differences of
10–20 mmHg between right upper limb and lower limbs
are considered significant. In neonates with PPHN and
atrial-level right-to-left shunting without a significant
ductal shunt, both the right arm and the right leg satura-
tions will be low. Conversely, babies with PDA and
coarctation of the aorta might have differential cyanosis.
In PPHN, hypoxemia is often labile unlike fixed hypox-
emia seen in cyanotic CHD. Hyperoxia test (obtaining
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gen) and/or hyperoxia-hyperventilation (hyperoxia and
alkalosis to induce pulmonary vasodilation and improve
PaO2) is no longer widely practiced due to the known
adverse effects of hyperoxia and alkalosis. It can be
avoided by confirming elevated pulmonary pressures by
an early echocardiogram, when available.
Echocardiography is gold standard to confirm the
diagnosis, and to monitor the efficacy of specific thera-
peutic interventions [57]. Measurement of the direction
of ductal and foramen ovale shunt, flattening or left-
deviation of the interventricular septum and tricuspid
regurgitation velocity with simultaneous systemic blood
pressure measurement provides an indication of right-
sided pressures and hemodynamic physiology.
B-type natriuretic peptide (BNP) concentrations in
plasma correspond well with echocardiographic findings
of ventricular strain [58]. Reynolds et al. suggested BNP
as an early indicator of PPHN in the presence of respira-
tory illness in neonates without CHD [59]. BNP has
been proposed as a biomarker in PPHN, especially to as-
sess efficacy of treatment and to predict rebound PPHN
[59,60]. However, its value in the practical management
of PPHN is presently unclear. Some centers obtain serial
(monthly) echocardiograms with BNP levels to screen
for pulmonary hypertension associated with BPD in pre-
term infants.
Severity of PPHN
Severity of PPHN is commonly assessed by oxygenation
index (OI) and Alveolar-arterial oxygen difference (AaDO2).
OI is more commonly used during medical management
of PPHN since it takes ventilator support into the consid-
eration and is calculated as
OI ¼ MAP  FiO2  100=PaO2
where MAP is the mean airway pressure in cmH2O,
FiO2 is the fraction of inspired oxygen, and PaO2 is
partial pressure of oxygen in arterial blood (in mmHg).
Hypoxemic respiratory failure can be classified into mild
(OI ≤ 15), moderate (OI > 15 to 25), severe (OI 25 to 40)
and very severe (OI > 40) [61]. Disadvantages of OI
include:(a) it can be manipulated by changing FiO2 or
MAP or based on the type of ventilator; (b) it requires
arterial access; (c) the value may vary based on the site
of arterial access – right radial (preductal) vs. umbilical
or posterior tibial (postductal). More recently, oxygen
saturation index (OSI =MAP× FiO2 × 100/Preductal SpO2)
has been used in patients without arterial access [62]. If
preductal SpO2 is in the 70-99% range, OSI corresponds
to approximately half of OI (OSI of 8 =OI of 16) [63].
More research evaluating the clinical role for this non-
invasive index is needed prior to its widespread use.AaDO2 is the difference between Alveolar partial pres-
sure of oxygen and arterial partial pressure of oxygen
and is calculated using the following formula.
AaDO2 ¼ Patm‐ PH2Oð Þ  FiO2‐ PaO2‐ PaCO2= RQ
Patm is the atmospheric pressure, which is usually
equal to 760 mmHg at sea level but needs to be adjusted
in high altitude. PH2O is the pressure of water vapor in
one ATM, which is usually considered to be 47 mmHg.
RQ is the respiratory quotient and equal to 1 if the en-
ergy source is purely carbohydrate or equal to 0.8 when
the nutritional source is a combination of carbohydrate,
protein, and lipid. The disadvantage of AaDO2 is that it
does not take ventilator pressure into account.
Management
The severity of PPHN can range from mild hypoxemia
with minimal respiratory distress to severe hypoxemia
and cardio-pulmonary instability that requires intensive
care support. Infants with PPHN require supportive care
tailored to the degree of hypoxemia and physiologic
instability. PPHN is often associated with underlying
parenchymal lung disease or systemic illness; therapy
should target the underlying disease (such as antibiotics
for sepsis).
Some hospital based practices such as cesarean sec-
tions, induction of labor at late-preterm or early-term
gestation, and the use of anesthetics and analgesics delay
pulmonary transition at birth. These infants present with
“delayed cardiorespiratory adaptation” must be closely
monitored and managed with appropriate respiratory
support. Respiratory support to recruit the lungs and
provide optimal inflation (while avoiding atelectasis and
hyperinflation) reduces PVR and is the key step in man-
agement of these infants and reduces the risk of PPHN.
Many infants with parenchymal lung disease have ele-
vated pulmonary arterial pressures. Premature therapy
with early initiation of an inhaled pulmonary vasodilator
such as iNO prior to lung recruitment is not beneficial
and optimal lung inflation with adequate PEEP and/or
surfactant often eliminates the need for specific pulmon-
ary vasodilator therapy.
Mild cases of PPHN with minimal or no respiratory
distress can be detected in the newborn nursery either
following a desaturation episode or by low postductal
oxygen saturation detected on critical congenital heart
disease screening [64]. These infants can be managed
with supportive care and oxygen supplementation. Close
monitoring is important as some of these infants may
rapidly deteriorate and require non-invasive ventilation
or intubation and mechanical ventilation. Infection should
be considered as elevated pulmonary pressures (often
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senting clinical feature of pneumonia or sepsis.
Supportive care: It is important to maintain normother-
mia and correct metabolic and hematologic abnormalities
such as hypoglycemia, hypocalcaemia, acidosis and poly-
cythemia. Sedation may be necessary to provide comfort
and decrease oxygen consumption from agitation in hyp-
oxemic or ventilated patients. Paralysis should be avoided
if possible, as it has been associated with increased mortal-
ity [1]. The goal of medical management is to selectively
reduce pulmonary arterial pressure and to maintain sys-
temic blood pressure.
Hyperventilation and alkali infusions to maintain an
alkaline pH were strategies previously in use but should
be avoided because of associated concerns of impaired
cerebral perfusion and sensorineural deafness with re-
spiratory alkalosis have been raised [65,66]. Similar or
improved outcomes with less chronic lung disease were
also observed in infants with PPHN maintaining normal
PCO2 (45–60 mmHg) [67,68]. Alkali infusion was asso-
ciated with increased use of ECMO and need for oxygen
at 28 days [1]. Thus, lack of convincing data to support
hyperventilation/alkali infusion therapy along with better
therapeutic options including inhaled vasodilators have
led to decreased use of alkalosis. Most centers avoid
acidosis based on animal studies demonstrating exagger-
ated hypoxic pulmonary vasoconstriction with pH < 7.25
[69]. We recommend maintaining pH > 7.25, preferably
7.30 to 7.40 during the acute phase of PPHN.
Mechanical ventilation
Given the important contribution of parenchymal lung
disease in many cases of PPHN, pharmacologic pulmon-
ary vasodilation alone without lung recruitment would
not be expected to cause sustained clinical improvement
[70,71]. “Gentle” ventilation strategies with optimal
PEEP, relatively low PIP or tidal volume and a degree of
permissive hypercapnia are recommended to ensure ad-
equate lung expansion while limiting barotrauma and
volutrauma [68,72]. In newborns with severe lung dis-
ease, high frequency ventilation is frequently used to
optimize lung inflation and minimize lung injury [73]. If
a PIP of > 28 cmH2O or tidal volumes > 6 cc/kg are re-
quired to maintain PaCO2 < 60 mmHg on conventional
ventilation, we recommend switching to high frequency
(jet or oscillator) ventilation. In clinical studies using
iNO, the combination of high frequency ventilation and
iNO resulted in the greatest improvement in oxygen-
ation in PPHN associated with diffuse parenchymal lung
disease such as RDS and pneumonia [74,75].
Oxygen is a specific and potent pulmonary vasodilator
and increased oxygen tension is an important mediator
of reduction in PVR at birth. Avoiding hypoxemia by
mechanical ventilation with high concentrations of oxygenused to be a mainstay of PPHN management. Fetal lamb
studies demonstrate that increased fetal oxygen tension
augments endogenous NO release [76] and increased pul-
monary blood flow induced by rhythmic distention of the
lung and oxygen are mediated in part by endogenous NO
[77]. However, it has also been shown that brief exposure
to 100% oxygen in newborn lambs results in increased
contractility of pulmonary arteries [78], reduces response
to iNO [79,80] and increases the potential for oxidative
stress [81]. Reactive oxygen species (ROS), such as
superoxide interact with NO to form a potent oxidant
peroxynitrite capable of vasoconstriction and surfactant
inactivation [82]. In addition to direct inactivation of
NO, ROS can decrease eNOS activity, sGC activity and
increase PDE5 activity, resulting in decreased cGMP
levels and potentiation of pulmonary vasoconstriction.
In the ovine ductal ligation model of PPHN, maintain-
ing oxygen saturations in the 90-97% range results in
low PVR [80]. We recommend maintaining preductal
oxygen saturations in low to mid-90s with PaO2 levels
between 55 and 80 mmHg during management of in-
fants with PPHN.
Surfactant
Exogenous surfactant therapy improved oxygenation and
reduced the need for extracorporeal membrane oxygen-
ation (ECMO) in neonates with PPHN secondary to par-
enchymal lung disease such as RDS, pneumonia/sepsis
or MAS. This multicenter trial also demonstrated that
this benefit was greatest for infants with mild to moderate
disease, and with an OI of 15–25 [83]. A post-hoc analysis
of the randomized trial of early nitric oxide use showed
that early use of surfactant prior to randomization de-
creased the risk of death/ECMO especially in infants with
parenchymal lung disease [84]. Over the past decade, the
use of surfactant in treating secondary PPHN and respira-
tory failure has increased and might have contributed to
improved effectiveness of iNO with reduced need for
ECMO. Surfactant inactivation and deficiency are ob-
served in many neonatal respiratory disorders such as
pneumonia, RDS and MAS. We recommend that infants
with PPHN secondary to parenchymal lung disease re-
ceive a dose of surfactant rich in surfactant protein-B
(SP-B), such as calfactant - Infasurf® (ONY Inc, Amherst
NY) or poractant-α - Curosurf® (Chiesi Farmaceutici,
S.p.A, Parma, Italy). Synthetic surfactant (lucinactant,
Surfaxin, Discovery laboratories, Inc. Warrington PA)
rich in SP-B mimetics has been shown to be resistant to
inactivation and effective in animal studies [85,86] and
appears to be safe in children with HRF [87] but its effi-
cacy in term infants with hypoxic respiratory failure is
not known.
It is not clear if surfactant therapy is beneficial in in-
fants with CDH. Animal studies show benefit [88-90]
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use of surfactant [91]. We recommend administration of
surfactant only in the presence of clinical, radiological or
biochemical evidence of surfactant deficiency in CDH
and administer only 50% of the dose because of pulmon-
ary hypoplasia.
Inhaled Nitric Oxide (iNO)
Nitric Oxide is a potent vasodilator that has also been
shown to be an important regulator of vascular tone,
growth and remodeling [92]. In the endothelium, NO is
produced from the terminal guanidino nitrogen of L-
arginine on its conversion to L-citrulline by the enzyme
eNOS in a reaction that requires molecular oxygen [92].
As an inhaled vasodilator, iNO selectively dilates the
pulmonary circulation without a significant decrease in
systemic blood pressure (selective effect of iNO). Inhaled
NO is also preferentially distributed to the ventilated
segments of the lung, resulting in increased perfusion of
the ventilated segments, optimizing VQ match (micro-
selective effect of iNO). Studies have shown that iNO
therapy causes marked improvement in oxygenation in
term newborns with PPHN [93]. Multicenter random-
ized clinical studies subsequently confirmed that iNO
therapy reduces the need for ECMO in term neonates
with hypoxemic respiratory failure [94-96]. Inhaled NO
therapy has been approved by the FDA for clinical use
in term/near term newborn infants (>34 wks gestation)
with hypoxic respiratory failure and PPHN since 2000.
Initiation of iNO: There has been a debate regarding
the timing of initiation and optimum starting dose of
iNO in PPHN. An OI of 25 is associated with a 50% risk
of requiring ECMO or mortality [97] in the absence of
specific pulmonary vasodilator therapy. Konduri et al.
initially demonstrated that earlier initiation of iNO with
an OI of 15–25 did not reduce the need for ECMO but
may have a tendency to reduce the risk of progression to
severe hypoxemic respiratory failure [98]. Post-hoc ana-
lysis of the same study suggested that the use of surfac-
tant prior to randomization and enrollment (and use of
iNO) at an OI of ≤ 20 was associated with reduced inci-
dence of ECMO/death [84].
Dosing of iNO: Previous clinical trials suggested that
the ideal starting dose for iNO is 20 parts per million
(ppm) with the effective doses between 5 and 20 ppm
[99]. Doses > 20 ppm did not increase the efficacy and
were associated with more adverse effects in these in-
fants [95] such as elevated methemoglobin (>7%) and ni-
trogen dioxide (NO2) (>3 ppm) [93]. A dose of 5 ppm
results in improved oxygenation in PPHN. A dose of
20 ppm results in improved oxygenation and results in
the most optimal decrease in pulmonary to systemic ar-
terial pressure ratio [100]. To summarize, we recom-
mend initiation of iNO if OI is ~ 20 at a dose of 20 ppm.A complete response to iNO is defined as an increase in
PaO2/ FiO2 ratio of ≥ 20mmHg. (20-20-20 rule for ini-
tiation of iNO, Figure 4). Methemoglobin levels are
monitored at 2 and 8 hours after initiation of iNO and
then once a day for the duration of iNO therapy. Some
centers stop checking methemoglobin levels after the
first couple of days if levels are low (<2%) and iNO
dose remains ≤ 20 ppm. High inspired oxygen and high
mean iNO dose are risk factors for elevated
methemoglobin in term infants [101].
Weaning iNO: Due to rebound vasoconstriction and
resultant pulmonary hypertension on abrupt withdrawal,
iNO needs to be weaned gradually [102]. Weaning in
steps from 20 ppm gradually over a period of time be-
fore its discontinuation has been shown to prevent the
rebound effect [103]. If there is oxygenation response,
inspired oxygen concentration is first weaned below 60%
and then iNO is weaned only if PaO2 can be main-
tained ≥ 60mmHg (or preductal SpO2 ≥ 90%) for 60min
(60-60-60 rule of weaning iNO). At our center, we wean
iNO at a rate of 5 ppm every 4 hours. Once iNO dose is
5 ppm, gradual weaning by 1 ppm q 4 hours is per-
formed (Figure 4). Continuing iNO in the absence of a
response or not weaning iNO or extremely slow weaning
can potentially lead to suppression of endogenous eNOS
[104,105].
Management of iNO-resistant PPHN
In approximately a third of term and near-term infants
with PPHN, iNO does not result in sustained improve-
ment in oxygenation [95]. Adequate lung recruitment
(with surfactant and/or optimal PEEP/MAP preferably
with high frequency ventilation) is crucial to deliver iNO
to its target site – the pulmonary vasculature [106]. A
repeat echocardiogram to evaluate ventricular function
and severity of PPHN (and to rule out cyanotic CHD
such as total anomalous pulmonary venous return
(TAPVR) that may have been missed on the first echo-
cardiogram [107]) is the next step. Management of sys-
temic hypotension in PPHN is discussed below. If lung
recruitment and hemodynamic stability are achieved and
iNO is still not effective, patient should be managed in a
tertiary center with access to ECMO. Our recommen-
dations for management of iNO-resistant PPHN not
responding to iNO in spite of lung recruitment with
increased MAP and surfactant are outlined in Figure 5
and summarized here.
(1)Hemodynamic evaluation: A repeat echocardiogram
should be performed to evaluate structural heart
disease, left ventricular dysfunction, right ventricular
dysfunction, and ventricular output For example, if
left ventricular dysfunction is associated high left
atrial pressures and a left-to-right shunt at the level
Figure 4 Inhaled Nitric Oxide therapy in neonates with PPHN: The diagnosis of PPHN is based on clinical (labile hypoxemia and differential
cyanosis) or echocardiographic findings. Optimal oxygenation and lung recruitment with optimal lung inflation and surfactant in the presence of
parenchymal lung disease is the initial step in the management of PPHN. An OI of 20 is a reasonable threshold to initiate iNO. The presence of
hemodynamic instability and severe hypoxemia (OI ~ 40 range) is an indication for ECMO. See text for details. (copyright Satyan Lakshminrusimha).
Figure 5 Flow chart showing the author’s suggested guidelines for management of iNO resistant PPHN. (copyright Satyan Lakshminrusimha).
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shunt at the ductus arteriosus, iNO is contraindicated
and an inodilator such as milrinone should be initiated.
(2)Rapid deterioration with hemodynamic instability
should necessitate cannulation for ECMO (or
immediate transfer to an ECMO center).
(3)In the presence of systemic hypotension, a fluid
bolus (10 ml/kg of Lactated Ringers or isotonic
saline) followed by dopamine is recommended.
Some centers prefer the use of norepinephrine or
vasopressin. A cortisol level is drawn in these
patients. If the levels are low relative to the infant’s
stress level and there is no evidence of infection
(viral or bacterial), the authors recommend a stress
dose of hydrocortisone.
(4)If blood pressure is relatively stable but hypoxemia
persists, consider the use of PDE inhibitors.
Sildenafil is preferred if normal liver and ventricular
function are present and may have added benefit in
the context of prolonged hyperoxia. Ventricular
dysfunction or hepatic compromise are indications
for Milrinone rather than sildenafil as long as
normal renal function is present. Chronic therapy
(especially in the presence of CDH or BPD) involves
PDE 5 inhibitors and endothelin receptor
antagonists and non-invasive iNO (Figure 5).
Prostaglandin E1 (PGE1)
Aerosolized prostaglandin E1 (Alprostadil) has been
used to treat pulmonary hypertension in adults. In a
small pilot phase I-II study, Sood et al. suggested that
inhaled PGE1 was a safe and selective pulmonary vaso-
dilator in hypoxemic respiratory failure with or without
use of iNO [108]. PGE1 solution for aerosolization is
prepared from Alprostadil® (Prostin VR 500, Pfizer, New
York NY) and administered as a continuous nebulization
through a MiniHeart low flow jet nebulizer (WestMed
Inc, Tuczon, AZ) at 150–300 ng/kg/min diluted in saline
to provide 4 ml/hr [109].
Intravenous PGE1 has also been used in patients with
CDH in combination with iNO to promote pulmonary
vasodilation and to maintain ductal patency and reduce
right ventricular afterload [110].
Inhaled Prostacyclin (PGI2)
Prostacyclin administered intravenously is a common
therapy in adults with pulmonary arterial hypertension.
Inhaled PGI2 has been used in PPHN resistant to iNO at
a dose of 50 ng/kg/min. [111] The intravenous formu-
lation Flolan° (Glaxo-Wellcome, Middlesex, UK) is dis-
solved in 20 ml of manufacturer’s diluent (a glycine
buffer, pH −10). Fresh solution is added to the nebuli-
zation chamber every 4 hours [111]. The effect of such
alkaline pH on neonatal respiratory tract is not known.Phosphodiesterase inhibitors
a) Sildenafil (PDE 5 Inhibitor): Studies have shown that
cGMP is decreased in response to exogenous NO in ani-
mal models of PPHN [112], and increased clearance of
cGMP by one or more phosphodiesterases has been pro-
posed as one of the causes [113]. Sildenafil acts by inhi-
biting cGMP-specific phosphodiesterase type 5 (PDE 5),
an enzyme that promotes degradation of cGMP. Studies
have shown that oral sildenafil (dose range 1–2 mg/kg
every 6 h) improves oxygenation and reduces mortality,
in centers limited by non-availability of iNO and ECMO
[114,115].
Intravenous sildenafil was shown to be effective in
improving oxygenation in patients with PPHN with
and without prior exposure to iNO [116]. The use of
intravenous sildenafil should be restricted to refractory
cases at a center with ECMO back-up, due the poten-
tial risk of systemic hypotension [117] and pulmonary
hemorrhage, presumably due to sudden reversal of
ductal shunt [118]. Based on pharmacokinetic data in
neonates with PPHN, intravenous sildenafil is adminis-
tered as a load of 0.42 mg/kg over 3 hours (0.14 mg/kg/h)
followed by 1.6 mg/kg/day as a continuous maintenance
infusion (0.07 mg/kg/h).
b) Milrinone (PDE 3 Inhibitor): Milrinone inhibits PDE3
and increases concentration of cAMP in pulmonary and
systemic arterial smooth muscle and in cardiac muscle.
Milrinone relaxes pulmonary arteries in the fetal lamb
model of PPHN [119]. Infants with PPHN refractory to
iNO therapy have responded to IV milrinone in 3 case
series [120-122] and appears to be particularly useful in
the presence of ventricular dysfunction [123,124]. A load-
ing dose (50 mcg/kg over 30–60 min) followed by a main-
tenance dose (0.33 mcg/kg/min and escalated to 0.66 and
then to 1 mcg/kg/min based on response) is commonly
used. The loading dose is not recommended in the pres-
ence of systemic hypotension and in premature neonates
[123]. As with any systemic vasodilator, hypotension is a
clinical concern and blood pressure needs to be closely
monitored. A fluid bolus (10 ml/kg of Lactated Ringer’s
solution) prior to loading dose may decrease the risk of
hypotension. In addition, one case series described an in-
creased incidence of intracranial hemorrhage with the use
of milrinone in PPHN [121]. Milrinone may be the pul-
monary vasodilator of choice in the presence of PPHN
with left ventricular dysfunction (Figure 5).
Bosentan (Endothelin-1 receptor blocker)
Endothelin receptor antagonists are beneficial and well
tolerated in adult patients with pulmonary arterial
hypertension [125]. Initial reports suggested that bosen-
tan was an effective drug in the management of PPHN
[126]. The results of a multi-center, randomized,
double-blind, placebo-controlled exploratory trial of
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(2 mg/kg/dose BID) did not show any additive effect on
top of iNO in term neonates with PPHN [127]. How-
ever, endothelin receptor antagonists may have a role in
the management of chronic pulmonary hypertension as-
sociated with BPD or CDH.
Steroids
Antenatal betamethasone attenuated oxidative stress and
improved in vitro response to vasodilators in a fetal
lamb model of pulmonary hypertension [128]. Glucocor-
ticoids have been found to improve oxygenation and at-
tenuate the pulmonary hypertensive response in animal
models of meconium aspiration syndrome, which is a
common cause of PPHN [129]. Steroids have been re-
ported to decrease hospital stay and duration of oxygen
use in infants with meconium aspiration [130,131]. It is
proposed that hydrocortisone attenuates ROS production
by induction of superoxide dismutase and normalization
of PDE5 activity [132]. Looking at the evidence this far, we
do not recommend routine use of steroids in patients with
PPHN especially if there is suspicion of viral or bacterial
sepsis. Anecdotal use of stress dose hydrocortisone in iNO
resistant PPHN associated with systemic hypotension in
our unit has resulted in stabilization of systemic blood
pressure and improved oxygenation possibly secondary to
hemodynamic stability and PDE-5 inhibitory effects [133].
Extracorporeal Membrane Oxygenation (ECMO)
ECMO is a technique of modified cardiopulmonary by-
pass used over a prolonged period to support heart and
lung function. The use of neonatal ECMO has declined
from a peak of 1516 cases per year in 1992 to 750–865
cases/year from 2008 to 2012. This decline is likely due
to improvements in both perinatal care and availability
of advanced therapies for neonatal hypoxemic respiratory
failure including high-frequency ventilators, surfactant,
and iNO [134]. In newborns with PPHN, mechanical ven-
tilation with oxygen and iNO is the initial treatment, but
prolongation of iNO with high oxygen levels may induce
chronic lung disease and extend the length of stay in the
NICU [135]. On the other hand, initiating ECMO too
early may expose newborns to major vessel cannulation
and systemic anticoagulation [136]. General accepted cri-
teria to start ECMO is persistent hypoxemia (with an OI
of >40 or AaDO2 > 600 in spite of aggressive medical
management of PPHN with mechanical ventilation and
iNO) and the presence of hemodynamic instability
(Figure 5).
Management of systemic hypotension in PPHN
Systemic hypotension is common in infants with PPHN
and the causes are outlined in Figure 6. Decreased sys-
temic blood pressure exacerbates right-to-left shunt andworsens hypoxemia in PPHN. The cause of systemic
hypotension should be addressed first – administration
of volume bolus in hypovolemia, decrease in MAP in
the presence of hyperinflation and antibiotics for sepsis.
The use of dopamine to increase systemic blood pres-
sure to reduce right-to-left shunt is a common practice.
Such a practice is effective in the presence of systemic
hypotension. However, increasing systemic pressure to
supraphysiologic levels is not recommended. In some
patients with PPHN, the presence of a patent ductus
arteriosus acts as a pop-off valve, limiting right ventricu-
lar preload and dysfunction. Increasing systemic blood
pressure limits right-to-left shunt across the PDA and
may add to right ventricular strain. In addition, the op-
timal therapy for reduced pulmonary blood flow is se-
lective pulmonary vasodilation. Instead, if pulmonary
blood is forced by higher systemic pressure (by limiting
right-to-left shunts) through a constricted pulmonary
circuit, endothelial dysfunction due to increased shear
stress [47] is likely to exacerbate PPHN. Dopamine
(especially at > 10 mcg/kg/min) is not selective to sys-
temic vasculature and can increase pulmonary arterial
pressure in PPHN [106]. Norepinephrine infusion is
also effective in stabilizing systemic blood pressure and
improving oxygenation in neonates with PPHN [137].
Vasopressin may be an effective therapeutic agent with
some selectivity to systemic vasoconstriction [138]. As
mentioned in the previous paragraph, hydrocortisone
may also be effective to stabilize blood pressure in
PPHN.
Asphyxia, hypothermia and management of PPHN
Asphyxia is associated with hypoxemia and acidosis. In-
fants with asphyxia also have evidence of surfactant defi-
ciency and/or meconium aspiration syndrome (Figure 7)
[139]. The use of moderate hypothermia (33.5°C for
72 hours) does not result in a significant increase in the
incidence of PPHN (25% vs. 22% with conventional
management without hypothermia) [140]. However, as
compared to moderated hypothermia (33.5°C), deeper
whole-body cooling to 32°C is associated with a ten-
dency to increased PPHN (34 vs 25%, p-0.06), increased
need for inhaled NO (34 vs 24%, p-0.03) and ECMO (9
vs 4%, p-0.005) [141]. Case reports indicate that patients
with hypoxemic respiratory disorders prior to the onset
of cooling (especially those that need > 50% inspired oxy-
gen and/or iNO) [142], may experience exacerbation of
PPHN with hypothermia and/or rewarming [143]. Mild
therapeutic hypothermia by itself is not a cause for
PPHN. However, infants predisposed to elevated PVR
due to the presence of asphyxia and respiratory disease
may not tolerate hypothermia induced pulmonary vasocon-
striction [144]. These findings emphasize the need for
close monitoring of core temperature, systemic/pulmonary
Figure 6 Causes of hypotension in infants with PPHN: Sepsis and hypoxia causes intravascular oligemia due to capillary leak or due to systemic
vasodilation. Neonates with PPHN often require high mean airway pressure that impedes venous return to the right side of heart. Increased
pulmonary vascular resistance results in less blood flow through pulmonary circulation reducing left ventricular preload. The deviation of the
interventricular septum towards left ventricle further impedes left ventricular filling. Neonates with PPHN secondary to sepsis, hypoxia and CDH
can also experience systemic hypotension secondary to left ventricular dysfunction. (copyright Satyan Lakshminrusimha).
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rewarming for asphyxia.
In many centers, confusion exists regarding optimal
reporting of PaCO2 during whole-body hypothermia.
The laboratory may report PaCO2 levels either at baby’s
temperature (known as the pH-stat method) or
corrected for 37°C (alpha-stat method). Decreasing
temperature increases the solubility of CO2 in the
blood and decreases PaCO2 and may have implications
for PPHN management with potential of overventila-
tion or underventilation. We recommend the pH-stat
method and reporting of PaCO2 at actual (and not
corrected) body temperature.
Long term outcome of PPHN
PPHN is a syndrome associated with significant long-
term morbidity, irrespective of the treatment modality.
These infants suffer from long-term consequences such
as neurodevelopmental, cognitive and hearing abnormal-
ities [145-147]. Thus, it is essential to provide long-term
multidisciplinary follow-up after discharge. Konduri et al.in their long-term follow-up of infants randomized to
early iNO in PPHN, noted neurodevelopmental impair-
ment in about 25% of infants and hearing impairment in
approximately 23% [145]. Long-term neurodevelopmental
outcome at school age for neonates with PPHN critical
enough to receive inhaled NO or ECMO is generally
encouraging. Rosenberg et al. reported that among 109
school age survivors of PPHN (77 of whom received
inhaled NO and 12 that required ECMO), medical,
neurodevelopmental and behavioral outcomes did not
differ between children treated with iNO, with or with-
out ECMO, and those managed with no exposure to
iNO. However, 24% had persistent respiratory prob-
lems, 60% had abnormal chest X-rays and 6.4% had
some degree of sensorineural hearing loss. Overall,
9.2% of the cohort had a full scale IQ less than 70 and
7.4% had an IQ from 70 to 84 [148]. The UK collabora-
tive trial randomized critically ill neonates into transfer
to a regional center for ECMO or continued conven-
tional care at the local NICU. At 7 year follow-up,
mortality was significantly lower in the ECMO group
Figure 7 Asphyxia and PPHN: Fetal hypoxia (secondary to in-utero asphyxia and meconium aspiration) causes pulmonary vascular remodeling,
which down regulates iNO signaling pathways and causes PPHN. In infants with perinatal hypoxia, the combination of hypoxia and acidosis
increases the risk of PPHN. Preexisting PPHN may be exacerbated by therapeutic hypothermia. Errors in PaCO2 measurement secondary to body
temperature changes may result in fluctuations in PCO2 leading to changes in cerebral and pulmonary vascular resistance (see text for details).
(copyright Satyan Lakshminrusimha).
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neurodevelopmental and medical disabilities may re-
flect the severity of the underlying illnesses experi-
enced by these infants rather than complications of
iNO or ECMO. However, therapeutic interventions
such as hyperventilation are associated with sensori-
neural hearing loss and must be avoided [66,150].
Conclusions
Over the last two decades, management of infants with
PPHN has included improved with improved ventilation
strategies to optimize lung recruitment, provide “gentle”
ventilation and minimize oxygen toxicity paired with the
therapeutic use of surfactant and iNO. These changes
have led to a substantial decrease in the number of neo-
natal PPHN patients requiring ECMO for respiratory dis-
orders. Animal models have contributed to our
understanding of fetal circulation, pulmonary vascular
transition at birth and hemodynamic and biochemical ab-
normalities associate with PPHN. Further clinical research
into pulmonary vasodilator therapy, reversal of remodel-
ing of the pulmonary vasculature and right ventricle are
crucial. Two challenges which remain in the field of
PPHN include management of pulmonary hypoplasia
and pulmonary hypertension in CDH and BPD-
associated pulmonary hypertension in the premature in-
fant [97]. In addition, asphyxia (with or without MAS
and/or therapeutic hypothermia) remains an important
cause for PPHN worldwide. Further research to evaluateand develop appropriate strategies to ameliorate pul-
monary vascular disease in these conditions are
warranted.
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